Acute Stroke Clinical Trial
— PassOfficial title:
PG2 Injection 500 mg in Acute Stroke Study (Pass): A Randomized, Double-Blind, Placebo-Controlled Study of PG2 Injection 500 mg in Patients With Treatment Started Within 3-6 Hrs of the Onset of Acute Ischemic Stroke
Verified date | November 2016 |
Source | China Medical University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Department of Health |
Study type | Interventional |
The primary objective of this study is to evaluate the efficacy of PG2 Injection 500 mg
versus placebo, administered intravenously within 3-6 hrs of stroke onset to patients with
an acute ischemic stroke, as determined by Modified Rankin Scale (mRS) score at Day 90.
The secondary objectives are as follows:
- To evaluate the efficacy of PG2 Injection 500 mg versus placebo as determined by
Barthel Index (BI) score at Day 90.
- To evaluate the efficacy of PG2 Injection 500 mg in reducing the risk of recurrent
stroke, cardiovascular events and death of all causes.
- To evaluate the safety of PG2 Injection 500 mg treatment
Status | Completed |
Enrollment | 86 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients presenting with acute ischaemic stroke 2. Patient, or a family member with legally authorized responsibility, has given informed consent 3. Age =20 years 4. Infusion of study medication can be started within 3-6 hrs of stroke onset. 5. NIHSS score of = 7 - 24 Exclusion Criteria: 1. Intracranial haemorrhage (ICH) identified by CT or MRI 2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient having an NIHSS score of < 6 at randomization 3. Pre-stroke mRS score of = 2 (indicating previous disability) 4. Known allergy to Astragalus membranaceus or its mayor derivatives (polysaccharides) 5. Patients who are eligible for tPA treatment and has been treated with tPA. 6. Participation in any investigational study in the previous 30 days 7. Any terminal illness such that patient would not be expected to survive more than 1 year 8. Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study (this applies to patients with severe microangiopathy such as haemolytic uremic syndrome or thrombotic thrombocytopenic purpura). The judgment is left to the discretion of the Investigator 9. Pregnant women (clinically evident) 10. Previous stroke within last three months 11. Past history or clinical presentation of ICH, arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. 12. Current use of oral anticoagulants with prolonged prothrombin time (INR > 1.6) 13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hrs and a prolonged activated partial thromboplastin time exceeding the upper limit of the local laboratory normal range 14. Clinically significant hypoglycaemia (blood sugar < 50mg/dl) 15. Uncontrolled hypertension defined by a blood pressure > 185 mmHg systolic or >110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of "aggressive treatment" is left to the discretion of the responsible Investigator 16. Major surgery within the preceding 14 days which poses risk in the opinion of the Investigator |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | China Medical University Hospital | Taichung |
Lead Sponsor | Collaborator |
---|---|
China Medical University Hospital | Changhua Christian Hospital, Cheng Hsin Rehabilitation Medical Center, Chung Shan Medical University, En Chu Kong Hospital, Kaohsiung Medical University, Kaohsiung Veterans General Hospital., Kuang Tien General Hospital, National Cheng-Kung University Hospital, National Taiwan University Hospital, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University Shuang Ho Hospital, Taipei Medical University WanFang Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy variable is the percentage of patients who are categorized as good functional outcome with mRS <2 | 90 days | No | |
Secondary | Percentage of patients who achieve a Day 90 BI score of 95-100 Percentage of patients who are free of recurrent stroke, cardiovascular events and death of all causes. Percentage of patients who are free of adverse events | 90 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Enrolling by invitation |
NCT06074081 -
Comparison of 4-weeks of Motor Relearning Program and Mirror Therapy in Improving Upper Limb Motor Function in Stroke Patients.
|
N/A | |
Terminated |
NCT04039178 -
Efficacy of EMF BCI Based Device on Acute Stroke
|
N/A | |
Completed |
NCT04521634 -
Glycaemic Variability in Acute Stroke
|
||
Completed |
NCT03477188 -
The Effects of Somatosensory and Vestibular Rehabilitation Additional Conventional Therapy on Balance in Patients With Acute Stroke.
|
N/A | |
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT02677415 -
Impact of Anesthesia Type on Outcome in Patients With Acute Ischemic Stroke (AIS) Undergoing Endovascular Treatment
|
N/A | |
Recruiting |
NCT01541163 -
Heart and Ischemic STrOke Relationship studY
|
N/A | |
Completed |
NCT01210729 -
Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke
|
Phase 2 | |
Recruiting |
NCT00785343 -
Study of Robot-assisted Arm Therapy for Acute Stroke Patients
|
Phase 1 | |
Completed |
NCT04779710 -
How Does Dysphagia Assessment in Acute Stroke Affect Pneumonia?
|
||
Active, not recruiting |
NCT03635749 -
Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis
|
Phase 3 | |
Recruiting |
NCT06149754 -
BraiN20® Monitoring in Acute Stroke Undergoing Thrombectomy
|
||
Recruiting |
NCT04491695 -
Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
|
Phase 2/Phase 3 | |
Recruiting |
NCT04283760 -
Investigation of the Reliability and Validity of the Movement Imagination Questionnaire - Revised Second in Acute Stroke Patients
|
||
Recruiting |
NCT05454397 -
A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients
|
||
Completed |
NCT04488692 -
Early Functional Training in Acute Stroke Inpatient Ward
|
N/A | |
Recruiting |
NCT04214522 -
Reliability and Validity of the Kinesthetic and Visual Imagery Questionnaire in Acute Stroke Patients
|
||
Not yet recruiting |
NCT04157231 -
Essential Acute Stroke Care in Low Resource Settings: a Pilot studY
|
N/A | |
Recruiting |
NCT05469438 -
IMAS Optimization and Applicability in an Acute Stroke Setting.
|